CLINICAL_TRIALS
trial_result
· 2020-05-05
Clinical Trial Update: Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) [Phase 3]
Summary
Phase 3 trial update reporting efficacy and safety of nintedanib in progressive fibrosing interstitial lung disease (PF-ILD).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Lung Diseases, Interstitial | Phase 3 | Status: COMPLETED | Results posted: 2020-05-05